Rating: BUY (Initiation)
Target price: RMB156.93
Share price (10 Aug): RMB89.42
Market Cap (RMBm): 7,869.0
Up/downside: 75.5%
We initiate coverage with a BUY call and PT of RMB156.93 (75.5% upside potential). With China’s currently low flu vaccine coverage and Covid-19 raising overall vaccination awareness, we believe that growing total vaccination rates and the proportion of tetravalent flu vaccines would benefit the company, a key tetravalent flu vaccine manufacturer.
Core product, tetravalent flu virus split vaccines, performing well
GDK Biotechnology is a human vaccine manufacturer driven by R&D and sales. It was established in December 2008. Its tetravalent influenza virus split vaccine entered the market in 2019. In 2020, revenue amounted to RMB589m, up 777.3% yoy, and net profit turned around into the black at RMB155m. The company expects revenue of RMB31m-36m in 1H21 with a net loss of RMB33m-36m, due to strong seasonality in flu vaccine sales, where most of the annual net profit would be reflected in 2H21.
We expect China’s flu vaccination rates to improve; tetravalent flu vaccine production volume boom
Annual flu vaccination is the most effective measure to prevent flu, in our view. We believe China’s flu vaccination rate will improve. According to data from the Chinese Procuratorate, batch issues of flu vaccines in China in 2020 amounted to 58m doses, with a vaccination rate at less than 4.2% of the population. According to the Centers for Disease Control and Prevention in the US, the country’s flu vaccination rates for adults and children were at 48.4% and 63.8%, respectively. China’s tetravalent flu vaccine was first marketed in 2018 and the proportion of batch issuance of tetravalent flu vaccines was 58.4% in 2020. In 2013, the US began to market tetravalent flu vaccines, and by lot release volume, this type of vaccination accounted 86.6% for the total vaccines in the 2019-20 flu season. With China providing a wider coverage of tetravalent flu vaccine strains, and with the roll-out of tetravalent flu vaccine production capacity by Chinese vaccine companies, tetravalent flu vaccine volume will grow, in our view.
Rising tetravalent flu vaccine capacity is set to drive net profit growth
With GDK’s flu vaccine workshop design capacity at about 10m doses p.a., it produced 5.117m doses in 2020. The company is building a new tetravalent flu vaccine workshop with a capacity of 30m doses p.a. In addition, its research pipeline includes nine vaccines that cover five types of diseases. Among these, freeze-dried human rabies vaccine (Vero cells) has completed phase III clinical trials, and the design capacity of its rabies vaccine workshop is about 15m doses p.a.
Valuation and risks
We believe that China currently has a low flu vaccine coverage rate. Covid-19 has helped raise awareness of vaccination. Flu vaccination needs to be done every year. Tetravalent flu vaccines offer better protection. The overall vaccination rate and the rise in the proportion of tetravalent flu vaccines would benefit the company, which is a key tetravalent flu vaccine manufacturer. We expect revenue of RMB1.07bn/1.25bn/2.43bn, up 82.1%/16.3%/94.8% yoy, and net profit of RMB314m/377m/748m, up 102.5%/ 20.0%/ 98.7% yoy in 2021-2023E. Relative to peer PEs (44x on average), we assign a PE of 44x to GDK, corresponding to a market cap of RMB13.81bn. We derive a price target of RMB156.93. Risks include: China’s flu vaccine coverage rate falls below expectations; tetravalent flu vaccine proportion falls below expectations; tech know-how and R&D progress worsens; policy risks; vaccine product safety risks; intensifying competition; risks related to an overly simple product mix; a widening funding gap; and share price fluctuation risks related to new stock.
免责声明(DISCLAIMER):
此文件仅发给指定收件人或机构。其内容可能包含某种享有法律特权或者需要保密的信息。对于任何未经本公司授权而对本文件所载内容进行使用、披露、分发、变更之行为及由此产生的后果,天风国际证券集团有限公司及其联属公司和附属公司(「天风集团」)概不承担任何责任。如您并非此文件的指定收件人或机构,请立即通知天风集团,并立即销毁此文件。谢谢合作。
This message is intended only for the individual or entity to which it is addressed. It may contain legally privileged and/or confidential information. TF International Securities Group Limited and its affiliates and subsidiaries (「TF Group」) does not accept liability for the unauthorized use, disclosure, distribution and/or alteration of any information it contains or the consequences thereof. If you are not an intended recipient, please inform TF Group and destroy this message immediately. Thank you.
評級:買入(啟動)
目標價:156.93元人民幣
股價(8月10日):89.42元人民幣
市值(人民幣):7869.0
上漲/下跌:75.5%
我們以買入通知和156.93元的PT(75.5%的上行潛力)開始覆蓋。隨着中國目前流感疫苗覆蓋率較低,以及新冠肺炎提高了整體疫苗接種意識,我們認為,提高總接種率和四價流感疫苗的比例將使該公司受益,該公司是四價流感疫苗的主要製造商。
核心產品,四價流感病毒裂解疫苗,表現良好
GDK生物技術是一家以研發和銷售為動力的人類疫苗製造商。它成立於2008年12月。其四價流感病毒裂解疫苗於2019年進入市場。2020年營收達到5.89億元,同比增長777.3%,淨利潤扭虧為盈,達到1.55億元。該公司預計,由於流感疫苗銷售具有很強的季節性,21季度營收將達到3100萬元至3600萬元人民幣,淨虧損3300萬元至3600萬元人民幣。該公司的大部分年度淨利潤將反映在21季度。
我們預計中國流感疫苗接種率將有所提高,四價流感疫苗產量激增
在我們看來,每年接種流感疫苗是預防流感的最有效措施。我們相信中國的流感疫苗接種率將會提高。根據中國檢察院的數據,2020年中國流感疫苗批次發行量為5800萬劑,疫苗接種率不到總人口的4.2%。根據美國疾病控制和預防中心的數據,該國成人和兒童的流感疫苗接種率分別為48.4%和63.8%。我國四價流感疫苗於2018年首次上市,2020年四價流感疫苗批次發放比例為58.4%。2013年,美國開始銷售四價流感疫苗,按批次發行量計算,這類疫苗佔2019-20年流感季節疫苗總數的86.6%。我們認為,隨着中國提供更廣泛的四價流感疫苗毒株,以及中國疫苗公司推出四價流感疫苗產能,四價流感疫苗的數量將會增長。
四價流感疫苗產能上升將推動淨利潤增長
GDK的流感疫苗車間設計能力約為每年1000萬劑,2020年生產了511.7萬劑。該公司正在建設一個新的四價流感疫苗車間,年生產能力為3000萬劑。此外,它的研究流水線包括覆蓋五種疾病的九種疫苗。其中,凍幹人用狂犬病疫苗(Vero細胞)已完成三期臨牀試驗,其狂犬病疫苗車間設計能力約為每年1500萬劑。
估值和風險
We believe that China currently has a low flu vaccine coverage rate. Covid-19 has helped raise awareness of vaccination. Flu vaccination needs to be done every year. Tetravalent flu vaccines offer better protection. The overall vaccination rate and the rise in the proportion of tetravalent flu vaccines would benefit the company, which is a key tetravalent flu vaccine manufacturer. We expect revenue of RMB1.07bn/1.25bn/2.43bn, up 82.1%/16.3%/94.8% yoy, and net profit of RMB314m/377m/748m, up 102.5%/ 20.0%/ 98.7% yoy in 2021-2023E. Relative to peer PEs (44x on average), we assign a PE of 44x to GDK, corresponding to a market cap of RMB13.81bn. We derive a price target of RMB156.93. Risks include: China’s flu vaccine coverage rate falls below expectations; tetravalent flu vaccine proportion falls below expectations; tech know-how and R&D progress worsens; policy risks; vaccine product safety risks; intensifying competition; risks related to an overly simple product mix; a widening funding gap; and share price fluctuation risks related to new stock.
免責聲明(DISCLAIMER):
此文件僅發給指定收件人或機構。其內容可能包含某種享有法律特權或者需要保密的信息。對於任何未經本公司授權而對本文件所載內容進行使用、披露、分發、變更之行為及由此產生的後果,天風國際證券集團有限公司及其聯屬公司和附屬公司(「天風集團」)概不承擔任何責任。如您並非此文件的指定收件人或機構,請立即通知天風集團,並立即銷燬此文件。謝謝合作。
此郵件僅適用於其收件人或實體。它可能包含法律特權和/或機密信息。TF國際證券集團有限公司及其聯屬公司和附屬公司(“TF集團”)不對其包含的任何信息的未經授權使用、披露、分發和/或更改或由此產生的後果承擔責任。如果您不是預期的收件人,請通知TF集團並立即銷燬此郵件。謝謝。